Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp
SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding
Executive Summary
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
You may also be interested in...
Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.
Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Finance Watch: Two New VC Funds Target Early Stage And Beyond
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.